Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
McKesson
AstraZeneca
Johnson and Johnson
Boehringer Ingelheim

Last Updated: October 16, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,415,311

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,415,311 protect, and when does it expire?

Patent 8,415,311 protects SOOLANTRA and is included in one NDA.

This patent has thirty-one patent family members in twenty-three countries.

Summary for Patent: 8,415,311
Title:Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Abstract: Dermatological conditions/afflictions such as rosacea, common acne, seborrheic dermatitis, perioral dermatitis, acneform rashes, transient acantholytic dermatosis, and acne necrotica miliaris, most notably rosacea, are treated by topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective amount of ivermectin.
Inventor(s): Manetta; Vincent (Bordentown, NJ), Watkins; Gary R. (Piscataway, NJ)
Assignee: Galderma S.A. (Cham, CH)
Application Number:13/310,633
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,415,311
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 8,415,311

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Galderma Labs Lp SOOLANTRA ivermectin CREAM;TOPICAL 206255-001 Dec 19, 2014 RX Yes Yes   Request a Trial   Request a Trial Y TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.   Request a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,415,311

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France03 05048Apr 24, 2003

International Family Members for US Patent 8,415,311

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 044050   Request a Trial
Austria 516037   Request a Trial
Australia 2004231323   Request a Trial
Brazil PI0410503   Request a Trial
Canada 2522579   Request a Trial
China 103800353   Request a Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Colorcon
McKinsey
Boehringer Ingelheim
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.